Identification of Coinfections by Viral and Bacterial Pathogens in COVID-19 Hospitalized Patients in Peru: Molecular Diagnosis and Clinical Characteristics.

Autor: Pérez-Lazo G; Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru., Silva-Caso W; Centre of Research and Innovation, Faculty of Health Sciences, School of Medicine, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.; Laboratorio de Biologia Molecular, Instituto de Investigación Nutricional, Lima 15024, Peru., Del Valle-Mendoza J; Centre of Research and Innovation, Faculty of Health Sciences, School of Medicine, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.; Laboratorio de Biologia Molecular, Instituto de Investigación Nutricional, Lima 15024, Peru., Morales-Moreno A; Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru., Ballena-López J; Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru., Soto-Febres F; Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru., Martins-Luna J; Laboratorio de Biologia Molecular, Instituto de Investigación Nutricional, Lima 15024, Peru.; Facultad de Ciencias de la Salud, Universidad Tecnológica del Perú, Lima 15046, Peru., Carrillo-Ng H; Centre of Research and Innovation, Faculty of Health Sciences, School of Medicine, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.; Laboratorio de Biologia Molecular, Instituto de Investigación Nutricional, Lima 15024, Peru., Del Valle LJ; Barcelona Research Center for Multiscale Science and Engineering, Departament d'Enginyeria Química, EEBE, Universitat Politècnica de Catalunya (UPC), 08034 Barcelona, Spain., Kym S; Korea International Cooperation for Infectious Diseases, Chungnam National University College of Medicine, Daejeon 305764, Korea., Aguilar-Luis MA; Centre of Research and Innovation, Faculty of Health Sciences, School of Medicine, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.; Laboratorio de Biologia Molecular, Instituto de Investigación Nutricional, Lima 15024, Peru., Peña-Tuesta I; Centre of Research and Innovation, Faculty of Health Sciences, School of Medicine, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.; Laboratorio de Biologia Molecular, Instituto de Investigación Nutricional, Lima 15024, Peru., Tinco-Valdez C; Centre of Research and Innovation, Faculty of Health Sciences, School of Medicine, Universidad Peruana de Ciencias Aplicadas, Lima 15023, Peru.; Laboratorio de Biologia Molecular, Instituto de Investigación Nutricional, Lima 15024, Peru., Illescas LR; Division of Infectious Diseases, Guillermo Almenara Irigoyen National Hospital-EsSalud, Lima 15033, Peru.
Jazyk: angličtina
Zdroj: Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2021 Nov 07; Vol. 10 (11). Date of Electronic Publication: 2021 Nov 07.
DOI: 10.3390/antibiotics10111358
Abstrakt: The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae /Adenovirus (0.7%), Chlamydia pneumoniae /Adenovirus (0.7%), RSV-B/ Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae / Chlamydia pneumoniae /Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae .
Databáze: MEDLINE
Externí odkaz: